The aim of this study was to assess the effect of a rectal enema on intrafraction prostate motion. The selleck inhibitor
data from 12 patients with localised prostate cancer were analysed. Each patient underwent image-guided radiotherapy (RT), receiving a total dose of 70?Gy in 28 fractions. Rectal enemas were administered to all of the patients before each RT fraction. The location of the prostate was determined by implanting three fiducial markers under the guidance of transrectal ultrasound. Each patient underwent preparation for IGRT twice before an RT fraction and in the middle of the fraction. The intrafraction displacement of the prostate was calculated by comparing fiducial marker locations before and in the middle of an RT fraction. The rectal enemas were well tolerated by patients. The mean intrafraction prostate movement in 336 RT fractions was 1.11?��?0.77?mm (range 0.08�C7.20?mm). Intrafraction motions of 1, 2 and 3?mm were observed in 56.0%, 89.0% and 97.6% of all RT fractions, respectively. The intrafraction Vemurafenib concentration
movements on supero-inferior and anteroposterior axes were larger than on the right-to-left axes (P?<?0.05). The CTV-to-PTV margin necessary to allow for movement, calculated using the van Herk formula (2.5��?+?0.7��), was 1.50?mm. A daily rectal enema before each RT fraction was tolerable and yielded little intrafraction prostate displacement. We think the use of rectal enemas is a feasible method to reduce prostate movement during RT. ""Purpose: To analyse patterns of failure in patients with glioblastoma multiforme treated with concurrent radiation and temozolomide. Materials and Methods: A retrospective review of patients treated with concurrent radiation and temozolomide was performed. Twenty patients treated at the University of Alabama at Birmingham, with biopsy-proven disease, documented disease progression after treatment, and adequate radiation dosimetry and imaging records were <a href="http://www.selleck.cn/products/BEZ235.html
">NVP-BEZ235 included in the study. Patients generally received 46?Gy to the primary tumour and surrounding oedema plus 1?cm, and 60?Gy to the enhancing tumour plus 1?cm. MRIs documenting failure after therapy were fused to the original treatment plans. Contours of post-treatment tumour volumes were generated from MRIs showing tumour failure and were overlaid onto the original isodose curves. The recurrent tumours were classified as in-field, marginal or regional. Recurrences were also evaluated for distant failure. Results: Of the 20 documented failures, all patients had some component of failure at the primary site. Eighteen patients (90%) failed in-field, 2 patients (10%) had marginal failures, and no regional failures occurred. Four patients (20%) had a component of distant failure in which an independent satellite lesion was located completely outside of the 95% isodose curve.